BIO

Bio-Rad Laboratories, Inc. [BIO] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

BIO Stock Summary

Top 10 Correlated ETFs

BIO


Top 10 Correlated Stocks

BIO


In the News

10:25 22 Feb 2024 BIO

Bio-Rad (BIO) Q4 Earnings Beat, Revenues Miss, Margins Down

Bio-Rad (BIO) continues to experience weak demand for Life Science products in China.

06:31 22 Feb 2024 BIO

Bio-Rad Laboratories (BIO) Surpasses Q4 Earnings Estimates

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $3.10 per share, beating the Zacks Consensus Estimate of $2.93 per share. This compares to earnings of $3.31 per share a year ago.

12:36 22 Feb 2024 BIO

Bio-Rad Laboratories (BIO) to Post Q4 Earnings: What Awaits?

Ongoing weakness in the biopharma end markets, impacting the sales of Life Science tools and bioprocessing products, are likely to have impeded Bio-Rad's (BIO) Q4 revenues.

05:00 22 Feb 2024 BIO

Bio-Rad to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year 2023 on Thursday, February 15, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, dial 888-259-6580 within the U.S. or +1 416-764-8624 outsid.

12:46 22 Feb 2024 BIO

Bio-Rad (BIO) Faces Soft Industry-wide Demand, Macro Woes

Bio-Rad's (BIO) margin performance suffers due to elevated raw material costs, increased logistics costs and higher employee-related expenses.

01:33 22 Feb 2024 BIO

Bio-Rad (BIO) Misses Q3 Earnings Estimates, Cuts 2023 View

The deterioration in biopharma and early biotech customer spending and a challenging macroeconomic environment in China impact Bio-Rad's (BIO) Q3 performance.

08:04 22 Feb 2024 BIO

Bio-Rad Laboratories, Inc. (BIO) Q3 2023 Earnings Call Transcript

Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q3 2023 Results Conference Call October 26, 2023 5:00 PM ET Company Participants Edward Chung - Head, IR Norman Schwartz - CEO Ilan Daskal - EVP and CFO Andy Last - EVP and COO Simon May - President, Life Science Group Dara Wright - President, Clinical Diagnostics Group Conference Call Participants Brandon Couillard - Jefferies Patrick Donnelly - Citi Jack Meehan - Nephron Tim Daley - Wells Fargo Conor McNamara - RBC Capital Operator Good afternoon, ladies and gentlemen. Thank you for standing by.

02:17 22 Feb 2024 BIO

Bio-Rad Laboratories (BIO) to Post Q3 Earnings: What Awaits?

Bio-Rad (BIO) Life Science segment will likely have witnessed growth in Q3, driven by Droplet Digital PCR and qPCR products.

11:18 22 Feb 2024 BIO

Bio-Rad Laboratories (BIO) Earnings Expected to Grow: Should You Buy?

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

06:46 22 Feb 2024 BIO

New Strong Sell Stocks for September 19th

BIO, LPG and COLB have been added to the Zacks Rank #5 (Strong Sell) List on September 19, 2023.

BIO Financial details

Company Rating
Buy
Market Cap
9.92B
Income
-159.3M
Revenue
2.72B
Book val./share
289.2
Cash/share
60.63
Dividend
-
Dividend %
-
Employees
8K
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-58.05
Forward P/E
19.5
PEG
5.58
P/S
3.41
P/B
1.1
P/C
5.58
P/FCF
41.62
Quick Ratio
3.98
Current Ratio
5.64
Debt / Equity
0.14
LT Debt / Equity
0.14
-
-
EPS (TTM)
-5.72
EPS next Y
17.34
EPS next Q
3.28
EPS this Y
-185.4%
EPS next Y
-403.15%
EPS next 5Y
-403.15%
EPS last 5Y
NAN%
Revenue last 5Y
4.12%
Revenue Q/Q
-7.19%
EPS Q/Q
-109.22%
-
-
-
-
SMA20
6.39%
SMA50
8.82%
SMA100
-6.2%
Inst Own
51.52%
Inst Trans
0.82%
ROA
-1%
ROE
-2%
ROC
0.04%
Gross Margin
54%
Oper. Margin
15%
Profit Margin
-6%
Payout
-38980%
Shs Outstand
24.06M
Shs Float
20.3M
-
-
-
-
Target Price
565
52W Range
261.59-509.62
52W High
-33.56%
52W Low
+29.56%
RSI
62
Rel Volume
0.75
Avg Volume
224.47K
Volume
169.44K
Perf Week
6.98%
Perf Month
5.42%
Perf Quarter
-15.5%
Perf Half Y
-11.05%
-
-
-
-
Beta
0.886
-
-
Volatility
5.54%, 10.23%
Prev Close
-0.14%
Price
338.16
Change
-1.08%

BIO Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
76.7677.4685.5297.9794.08
Net income per share
12.158.93127.86142.33-121.79
Operating cash flow per share
9.5715.3419.3322.016.53
Free cash flow per share
5.2212.041617.962.7
Cash per share
28.537.5433.4829.3560.31
Book value per share
134.59192.84331.9458.15322.82
Tangible book value per share
123.03179.12315.39438298.02
Share holders equity per share
134.59192.84331.9458.15322.82
Interest debt per share
15.5315.521.210.4241.51
Market cap
6.93B11.04B17.35B22.54B12.52B
Enterprise value
6.94B10.82B16.7B22.08B13.29B
P/E ratio
19.196.284.565.31-3.45
Price to sales ratio
3.034.786.827.714.47
POCF ratio
24.2724.1230.1634.3364.41
PFCF ratio
44.5130.7336.4242.07155.99
P/B Ratio
1.731.921.761.651.3
PTB ratio
1.731.921.761.651.3
EV to sales
3.034.686.567.554.74
Enterprise value over EBITDA
18.9227.7529.1233.9720
EV to operating cash flow
24.323.6329.0433.6368.34
EV to free cash flow
44.5630.1135.0641.22165.5
Earnings yield
0.050.160.220.19-0.29
Free cash flow yield
0.020.030.030.020.01
Debt to equity
0.110.08000.12
Debt to assets
0.080.05000.09
Net debt to EBITDA
0.02-0.57-1.13-0.711.15
Current ratio
4.512.413.392.925.55
Interest coverage
-4.539.8118.8315.5612.66
Income quality
0.790.260.150.15-0.05
Dividend Yield
00.3501.575.44
Payout ratio
02.1808.31-18.8
Sales general and administrative to revenue
0.360000
Research and developement to revenue
0.090.090.090.090.09
Intangibles to total assets
0.060.050.040.030.05
Capex to operating cash flow
-0.45-0.22-0.17-0.18-0.59
Capex to revenue
-0.06-0.04-0.04-0.04-0.04
Capex to depreciation
-0.94-0.73-0.72-0.9-0.83
Stock based compensation to revenue
0.010.020.020.020.02
Graham number
191.42505.67977.171.21K940.55
ROIC
-0.020.030.030.030.03
Return on tangible assets
0.070.230.30.25-0.28
Graham Net
-5.04-18.83-49.39-88.14-45.65
Working capital
1.58B1.27B1.51B1.31B2.59B
Tangible asset value
3.67B5.35B9.39B13.07B8.88B
Net current asset value
436.51M-73.65M-952.84M-2.12B-728.44M
Invested capital
0.110.08000.12
Average receivables
429M392.91M406.05M421.48M459.09M
Average payables
285.64M275.78M324.71M390.63M374.38M
Average inventory
589.57M569.17M588.13M597.25M645.78M
Days sales outstanding
62.666260.1452.964.43
Days payables outstanding
90.5899.36119.38119.2897.49
Days of inventory on hand
200.12191.73205.02162.94212.61
Receivables turnover
5.835.896.076.95.67
Payables turnover
4.033.673.063.063.74
Inventory turnover
1.821.91.782.241.72
ROE
0.090.310.390.31-0.38
Capex per share
-4.35-3.3-3.32-4.05-3.83

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
22.924.622.8723.221.72
Net income per share
-5.5227.892.33-39.593.65
Operating cash flow per share
0.253.053.323.343.36
Free cash flow per share
-0.561.472.112.161.84
Cash per share
62.4160.5162.7558.8760.63
Book value per share
284.32323.93329.9287.75289.2
Tangible book value per share
259.94299.05305.05262.53264.42
Share holders equity per share
284.32323.93329.9287.75289.2
Interest debt per share
40.6740.7640.9141.2641.63
Market cap
12.4B12.48B14.18B11.13B10.43B
Enterprise value
13.08B13.25B14.91B11.94B11.17B
P/E ratio
-18.883.7751.39-2.3924.54
Price to sales ratio
18.2217.0920.9516.3416.5
POCF ratio
1.65K138.04144.49113.49106.76
PFCF ratio
-749.51287.01227.22175.46194.47
P/B Ratio
1.471.31.451.321.24
PTB ratio
1.471.31.451.321.24
EV to sales
19.2218.1422.0317.5317.68
Enterprise value over EBITDA
101.7582.36100.884.175.13
EV to operating cash flow
1.74K146.49151.97121.73114.35
EV to free cash flow
-790.59304.58238.99188.22208.3
Earnings yield
-0.010.070-0.10.01
Free cash flow yield
0000.010.01
Debt to equity
0.140.120.120.140.14
Debt to assets
0.10.090.090.10.1
Net debt to EBITDA
5.294.754.965.74.98
Current ratio
5.55.555.565.395.64
Interest coverage
7.9610.169.117.267.34
Income quality
-0.050.111.42-0.080.92
Dividend Yield
03.81.0300
Payout ratio
057.3212.6100
Sales general and administrative to revenue
00000
Research and developement to revenue
0.10.090.110.10.07
Intangibles to total assets
0.060.050.050.060.06
Capex to operating cash flow
-3.2-0.52-0.36-0.35-0.45
Capex to revenue
-0.04-0.06-0.05-0.05-0.07
Capex to depreciation
-0.74-1.17-1-0.97-1.18
Stock based compensation to revenue
0.020.020.020.020.03
Graham number
187.98450.83131.51506.3154.14
ROIC
0.010.010.010.010.01
Return on tangible assets
-0.010.060.01-0.10.01
Graham Net
-36.39-45.8-43.81-35.64-33.82
Working capital
2.57B2.59B2.69B2.56B2.59B
Tangible asset value
7.73B8.88B9.03B7.71B7.7B
Net current asset value
-464.7M-728.44M-626.45M-392.47M-332.98M
Invested capital
0.140.120.120.140.14
Average receivables
441.31M463.47M496.46M494.92M474.49M
Average payables
337.05M332.52M332.36M319.57M285.52M
Average inventory
671.49M702.58M736.13M764.77M776.21M
Days sales outstanding
57.1560.9666.2664.9665.12
Days payables outstanding
98.2789.0995.8685.9481
Days of inventory on hand
201.06194.3215.52219.36235.54
Receivables turnover
1.571.481.361.391.38
Payables turnover
0.921.010.941.051.11
Inventory turnover
0.450.460.420.410.38
ROE
-0.020.090.01-0.140.01
Capex per share
-0.81-1.58-1.21-1.18-1.51

BIO Frequently Asked Questions

What is Bio-Rad Laboratories, Inc. stock symbol ?

Bio-Rad Laboratories, Inc. is a US stock , located in Hercules of Ca and trading under the symbol BIO

Is Bio-Rad Laboratories, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $565. The lowest prediction is $565 and the highest is $565

What is BIO stock prediction ?

What is Bio-Rad Laboratories, Inc. stock quote today ?

Bio-Rad Laboratories, Inc. stock price is $338.16 today.

Is Bio-Rad Laboratories, Inc. stock public?

Yes, Bio-Rad Laboratories, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap